# Shoulder Innovations, Inc.

**SI**

NYSE; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001699350

# None

### No letter

3 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $169.9M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | thin data<br>not computable: dilution, distress, fortress balance sheet |
| **Inputs computable** | 3 of 14 |
| **Graded from** | filings received through Mar 10, 2026<br>235 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026 |
| **Last close** | $19.31<br>2026-10-30; market equity $402.0M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 10, 2026*

We are a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. We currently offer advanced implant systems for shoulder arthroplasty. These systems are a core element of our ecosystem, which we designed to improve core components of shoulder surgical care - preoperative planning, implant design and procedural efficiency - to benefit each stakeholder in the care chain. Our ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 63.6** | | | | | | |
| Gross profitability | 21.3% | 32.4% | | 63.6 | 366 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |

*one or more required annual facts are missing*

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Accruals ratio | not computable | (6.6%) | | | | |
| *a prior annual assets observation is required* | | | | | | |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 1* | | | | | | |
| **Solvency, sleeve percentile 13.2** | | | | | | |
| Twelve-month failure probability | not computable | 0.07% | | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | | |
| Altman Z double-prime | 7.68 | (0.35) | | 12.6 | 748 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 11.07x | 2.92x | | 13.9 | 829 | 2025-12-31 |
| **Growth and financing** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *four annual observations are required; found 1* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *four consecutive annual FCF observations are required; found 1* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *a prior annual working-capital observation is required* | | | | | | |
| Asset growth, three years | not computable | 2.2% | | | | |
| *four annual observations are required; found 1* | | | | | | |
| Net share issuance, one year | not computable | 2.5% | | | | |
| *two annual share counts are required; found 1* | | | | | | |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 3 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-10-30 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 67.0% | 7.3% | 82 |
| Distance from 52-week high | (21.1%) | (28.7%) | 60 |
| EBIT to enterprise value | not computable | (1.4%) | |
| Free cash flow yield | (9.0%) | (1.0%) | 33 |
| Book value to price | 0.31 | 0.28 | 53 |
| Sales to price | 0.12 | 0.30 | 29 |
| Composite equity issuance, five years | not computable | 20.5% | |
| Relative strength against the sector, log excess return | 0.30 | (0.14) | 82 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $24.5M |
| Operating cash flow, four quarters | -$37.1M |
| Months of runway | 7.9 |
| Days since last periodic filing | 86 (10-Q received Aug 6, 2026) |
| Median daily dollar volume, 63 sessions | $1.9M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $36.2M | 2025-12-31 | 2026-03-10 | 10-K | 26-000011 |
| 2 | assets | us-gaap:Assets | $169.9M | 2025-12-31 | 2026-03-10 | 10-K | 26-000011 |
| 3 | net income | us-gaap:NetIncomeLoss | -$40.4M | 2025-12-31 | 2026-03-10 | 10-K | 26-000011 |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$28.6M | 2025-12-31 | 2026-03-10 | 10-K | 26-000011 |
| 5 | current assets | us-gaap:AssetsCurrent | $157.2M | 2025-12-31 | 2026-03-10 | 10-K | 26-000011 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $14.2M | 2025-12-31 | 2026-03-10 | 10-K | 26-000011 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$97.4M | 2025-12-31 | 2026-03-10 | 10-K | 26-000011 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$26.3M | 2025-12-31 | 2026-03-10 | 10-K | 26-000011 |
| 9 | book equity | us-gaap:StockholdersEquity | $140.8M | 2025-12-31 | 2026-03-10 | 10-K | 26-000011 |
| 10 | liabilities | us-gaap:Liabilities | $29.2M | 2025-12-31 | 2026-03-10 | 10-K | 26-000011 |
| 11 | revenue | us-gaap:Revenues | $47.3M | 2025-12-31 | 2026-03-10 | 10-K | 26-000011 |
| 12 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $7.4M | 2025-12-31 | 2026-03-10 | 10-K | 26-000011 |
| 13 | depreciation amortization | us-gaap:Depreciation | $2.9M | 2025-12-31 | 2026-03-10 | 10-K | 26-000011 |
| 14 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$40.4M | 2025-12-31 | 2026-03-10 | 10-K | 26-000011 |
| 15 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2025-12-31 | 2026-03-10 | 10-K | 26-000011 |
| 16 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 20,647,526 | 2026-03-03 | 2026-03-10 | 10-K | 26-000011 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.